{
    "organizations": [],
    "uuid": "a327db43b52d44dde9b999056b11fa15146b331b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cesca-therapeutics-announces-first/brief-cesca-therapeutics-announces-first-evaluation-agreement-with-a-leading-u-s-academic-research-institution-for-x-series-products-idUSFWN1RU0U4",
    "ord_in_thread": 0,
    "title": "BRIEF-Cesca Therapeutics Announces First Evaluation Agreement With A Leading U.S. Academic Research Institution For X-Series Products",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 17 (Reuters) - Cesca Therapeutics Inc:\n* CESCA THERAPEUTICS ANNOUNCES FIRST EVALUATION AGREEMENT WITH A LEADING U.S. ACADEMIC RESEARCH INSTITUTION FOR X-SERIESâ„¢ PRODUCTS THAT PROVIDE AUTOMATED, CLOSED SYSTEM CELLULAR PROCESSING\n* CESCA THERAPEUTICS INC - CESCA WILL BE RESPONSIBLE FOR PROVIDING ITS X-SERIES PRODUCTS, ALONG WITH REQUIRED TRAINING AND SUPPORT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-17T20:39:00.000+03:00",
    "crawled": "2018-04-18T17:54:52.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "cesca",
        "therapeutic",
        "inc",
        "cesca",
        "therapeutic",
        "announces",
        "first",
        "evaluation",
        "agreement",
        "leading",
        "academic",
        "research",
        "institution",
        "product",
        "provide",
        "automated",
        "closed",
        "system",
        "cellular",
        "processing",
        "cesca",
        "therapeutic",
        "inc",
        "cesca",
        "responsible",
        "providing",
        "product",
        "along",
        "required",
        "training",
        "support",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}